drugset / Trial / NCT01133353

A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's Syndrome

NCT01133353

Phase 2 Withdrawn Bausch Health Americas, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this clinical trial is to study the therapeutic effect of tetrabenazine MR in children with Tourette's Syndrome, as measured by the improvement in total tic score of the Yale Global Tic Severity Scale (YGTSS).

Timeline

Start
2011-03
Primary completion
2011-11
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tetrabenazine Unknown 15 mg
Subject Tetrabenazine Unknown 30 mg
Subject Tetrabenazine Unknown 150 mg

Indications